GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Cyclically Adjusted Price-to-FCF

Biogen (BUE:BIIB) Cyclically Adjusted Price-to-FCF : 10.13 (As of Apr. 30, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Biogen Cyclically Adjusted Price-to-FCF?

As of today (2024-04-30), Biogen's current share price is ARS18095.50. Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ARS1,787.16. Biogen's Cyclically Adjusted Price-to-FCF for today is 10.13.

The historical rank and industry rank for Biogen's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BUE:BIIB' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 9.07   Med: 32.53   Max: 107.99
Current: 9.75

During the past years, Biogen's highest Cyclically Adjusted Price-to-FCF was 107.99. The lowest was 9.07. And the median was 32.53.

BUE:BIIB's Cyclically Adjusted Price-to-FCF is ranked better than
88.07% of 327 companies
in the Drug Manufacturers industry
Industry Median: 32.38 vs BUE:BIIB: 9.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogen's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ARS2,496.318. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ARS1,787.16 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biogen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Price-to-FCF Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.82 15.94 13.36 14.55 12.23

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.23 13.25 11.84 12.23 10.06

Competitive Comparison of Biogen's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted Price-to-FCF falls into.



Biogen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biogen's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=18095.50/1787.16
=10.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biogen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2496.318/129.4194*129.4194
=2,496.318

Current CPI (Mar. 2024) = 129.4194.

Biogen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 31.712 100.560 40.813
201409 30.251 100.428 38.984
201412 28.848 99.070 37.685
201503 23.779 99.621 30.892
201506 35.367 100.684 45.461
201509 26.675 100.392 34.388
201512 61.490 99.792 79.746
201603 57.291 100.470 73.799
201606 56.709 101.688 72.174
201609 48.313 101.861 61.384
201612 102.172 101.863 129.812
201703 -59.269 102.862 -74.571
201706 65.766 103.349 82.356
201709 111.619 104.136 138.720
201712 110.078 104.011 136.968
201803 119.200 105.290 146.518
201806 100.398 106.317 122.214
201809 281.634 106.507 342.222
201812 314.428 105.998 383.905
201903 264.383 107.251 319.032
201906 417.012 108.070 499.396
201909 487.242 108.329 582.100
201912 568.806 108.420 678.975
202003 432.298 108.902 513.746
202006 784.375 108.767 933.308
202009 518.074 109.815 610.562
202012 -247.203 109.897 -291.117
202103 400.066 111.754 463.304
202106 729.188 114.631 823.257
202109 489.163 115.734 547.004
202112 527.065 117.630 579.892
202203 75.582 121.301 80.641
202206 574.242 125.017 594.465
202209 577.583 125.227 596.922
202212 -302.554 125.222 -312.696
202303 522.038 127.348 530.530
202306 659.794 128.729 663.334
202309 1,219.991 129.860 1,215.856
202312 -130.395 129.419 -130.395
202403 2,496.318 129.419 2,496.318

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (BUE:BIIB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biogen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BUE:BIIB) Headlines

From GuruFocus

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Analyst Q&A Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at SVB Leerink CNS Forum (Virtual) Transcript

By GuruFocus Research 01-22-2024